#HappyNewYear from our team to yours! As we welcome 2025, we look forward to continuing preparations for our Phase 3 trial in patients with alcohol-associated #hepatitis (#AH) and remain committed to developing therapies to improve patients’ lives. Here’s to a year filled with progress and success!
DURECT Corporation的动态
最相关的动态
-
?? NEWS ?? The European Commission approved blinatumomab, a bispecific T-cell engager, as part of consolidation therapy for the treatment of adult patients with newly diagnosed Ph? CD19+ B-ALL. Read more here: https://loom.ly/GWnSrVw #leusm #ALLsm #MedNews
-
-
Good drug and less toxicity profile. it is good to use in early setting.
BREAKING: The #FDA has granted asciminib accelerated approval for the treatment of adult patients with newly diagnosed Ph+ CML in chronic phase. #leusm https://lnkd.in/e36XrC_q
-
-
Counsel, Porzio, Bromberg & Newman, P.C. (Life Sciences Legal, Regulatory, and Compliance)
Check out the below article I co-authored about compliance considerations for clinical trial recruitment activities and communications. Let me know what you think!
Clinical trial sponsors face recruitment challenges, especially for rare diseases and complex therapies. In Clinical Leader, Michelle Axelrod and Noah Goldstein discuss practical compliance considerations for communications and payments related to recruitment. Read the article: https://bit.ly/3WfDkzc #ClinicalTrials #LifeSciences #FDA
-
-
#DidYouKnow that MASH is the leading cause of liver-related morbidity and can cause?fibrosis and scarring?which can lead to?cirrhosis? Currently, there is only one therapy approved for the treatment of MASH which underlines the urgent unmet need for additional treatment options for these patients. At Aligos, we are developing ALG-055009, a THR-β agonist, as a potential best-in-class #MASH treatment. Learn more about our approach to advancing patient care (bit.ly/3A9M1Tv) and check out this article by The New York Times for a deeper look into the rising impact of MASH:?bit.ly/3YGvw9R #LiverAwarenessMonth #LiverDisease
-
Award-Winning Sales Executive Driving Exceptional Revenue Growth in Healthcare & Pharma Through Strategic Data-Driven Decision Making & Lasting Client Relationships
Check out how UBC's #patientsfirst approach helped an underserved population with a rare disease....click below and order your free copy of this nicely done case study!
UBC’s patient access programs are purpose-built to meet the unique needs of your patient and therapy. Find out how considering the patient population first helped improve patient adherence by up to 20% for rare disease patients: https://hubs.li/Q02zmy9b0 #PatientsFirst #PatientAccess #RareDisease #Pharma
-
?New study alert connected with the Shape MS project! ??New studies show that treatment with rituximab, a CD20 inhibitor used off-label for MS patients, can stabilize disability progression and reduce disease activity in people with secondary progressive MS. ??“Considering the observed benefits, continuation of [rituximab] treatment in MS patients upon reaching the progressive phase could be a viable option, particularly for those with active disease,” the team wrote. ?? Find more information by clicking here: https://shorturl.at/bYkvF ??Click here to be updated about the #ShapeMS project: https://www.shape-ms.eu/ #EurosuccessCy?#ErasmusPlus?#multiplesclerosis?#mswarrior?#msawareness
-
-
Chief Commercial Officer I CCO I SVP I Driving Revenue Growth Through Creative Strategy & Effective Tactical Execution | Building High Performing Teams & Winning Cultures | Leading Healthcare Tech Pharmaceutical Services
In Patient Access, it is critical to partner with a solution that is "Purpose built, well defined and custom tailored to your patient and their therapy". As healthcare moves from population health to personalized medicine & individualized therapy, so should your patient access programs. Read here about how to improve patient adherence by up to 20%.
UBC’s patient access programs are purpose-built to meet the unique needs of your patient and therapy. Find out how considering the patient population first helped improve patient adherence by up to 20% for rare disease patients: https://hubs.li/Q02zmy9b0 #PatientsFirst #PatientAccess #RareDisease #Pharma
First-in-Class Therapy Succeeds with Personalized Patient Services
-
SEE THE POSITIVES OF KNOWING THE NEGATIVE Silent rejection is common, happening in 25% of transplant patients. But knowing earlier = treating earlier. Visit https://lnkd.in/gXbwQER8 to learn more! #SilentRejection #KidneyTransplantRejection #GetAheadOfRejection #TruGraf #TGI #TransplantGenomics
-
-
SEE THE POSITIVES OF KNOWING THE NEGATIVE Silent rejection is common, happening in 25% of transplant patients. But knowing earlier = treating earlier. Visit https://lnkd.in/gXbwQER8 to learn more! #SilentRejection #KidneyTransplantRejection #GetAheadOfRejection #TruGraf #TGI #TransplantGenomics
-
-
SEE THE POSITIVES OF KNOWING THE NEGATIVE Silent rejection is common, happening in 25% of transplant patients. But knowing earlier = treating earlier. Visit https://lnkd.in/gXbwQER8 to learn more! #SilentRejection #KidneyTransplantRejection #GetAheadOfRejection #TruGraf #TGI #TransplantGenomics
-
